- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, RSL3 / Stanford University
Journal: Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. (Pubmed Central) - Mar 25, 2022 Cetuximab promoted RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 in KRAS mutant CRC cells, and this was further demonstrated in a xenograft nude mouse model. Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. (Pubmed Central) - Mar 24, 2022 In turn, KRAS-reprogrammed macrophages were shown to not only promote tumor progression but also induce the resistance of tumor cells to cetuximab therapy...Mutant KRAS increased the production of reactive oxygen species, an inhibitor of prolyl hydroxylase activity which decreases HIF-1α hydroxylation, leading to enhanced HIF-1α stabilization. This cell-extrinsic mechanism awards KRAS a critical role in engineering a permissive microenvironment to promote tumor malignancy, and may present new insights on potential therapeutic defense strategies against mutant KRAS tumors.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: TIME-PRODIGE 28 UNICANCER: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - Mar 24, 2022 P2, N=139, Completed, This regimen may be considered an attractive therapeutic strategy due to its simplified administration, decreased total number of chemotherapy cycles, and treatment tolerability. Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Oct 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, IO biomarker: Interleukin-33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer. (Pubmed Central) - Mar 23, 2022 Effective cetuximab treatment induced a change of IL-33 and OPN at the early stage and triggered the NK cells antitumor activity. Consequently, significantly increased IL-33 level and decreased OPN level in the peripheral blood at the early treatment are proposed as potential predictors of cetuximab treatment efficacy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Cancer of the Larynx and Hypopharynx. (Pubmed Central) - Mar 19, 2022 In addition, the immune system is vital in the prevention of recurrence, and various immunomodulators against programmed cell death receptor 1 are being investigated. Multidisciplinary management of the patient with laryngeal and hypopharyngeal is key, as many vital functions are affected by this devastating disease.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: a case report. (Pubmed Central) - Mar 18, 2022 We report here, for the first time, the case of a patient with BRAF V600E, PIK3CA and SMAD4 mutated and dMMR/MSI mCRC, in whom we observed an atypical response pattern under the sequence of pembrolizumab followed by the doublet encorafenib and cetuximab treatment. The patient was progressive after a single cycle of pembrolizumab followed by a rapid complete response after only two months of treatment with encorafenib and cetuximab, discovered during R0 cyto-reduction surgery for peritoneal carcinomatosis.
- |||||||||| BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Mar 17, 2022 P1, N=150, Recruiting, The heterogeneity in the ex vivo response of cetuximab, pembrolizumab and both combined with and without IFN-γ stimulation identifies subgroups of HNSCC patients with deviating OS. Not yet recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lumigan (bimatoprost) / Senju, AbbVie
Review, Journal: Eyelash Trichomegaly: A Systematic Review of Acquired and Congenital Etiologies of Lengthened Lashes. (Pubmed Central) - Mar 17, 2022 Congenital disorders associated with lengthened eyelashes included Cantú syndrome, CHOPS syndrome, Coffin-Siris syndrome, congenital heart disease, Cornelia de Lange syndrome, Costello syndrome, familial trichomegaly, Floating Harbor syndrome, Hermansky-Pudlak syndrome, Kabuki-Makeup syndrome, KBG syndrome, Oliver-McFarlane syndrome, Rubinstein-Taybi syndrome, and Smith-Magenis syndrome. While the most common cause of eyelash trichomegaly is topical bimatoprost use, better understanding of pathways implicated in eyelash trichomegaly may lead to the discovery of additional medications to stimulate eyelash growth and create avenues for future therapeutic interventions.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal, Heterogeneity: Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging. (Pubmed Central) - Mar 17, 2022 Biopsies can be highly invasive procedures and provide a limited sample of molecular expression within a tumor. Our nanoparticle-based Raman imaging approach offers the potential to provide non-invasive and more comprehensive molecular imaging and an alternative to the current clinical gold standard of immunohistochemistry.
- |||||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 16, 2022 P3, N=702, Active, not recruiting, The data from this descriptive study suggests that immune checkpoint blockade, whether single agent or in combination, may be a suitable therapeutic option for a disease for which targeted approaches do not currently exist. Trial completion date: May 2022 --> Sep 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Comparative study on application ofLu-labeled rituximab, tetulomab, cetuximab and huA33 monoclonal antibodies to targeted radionuclide therapy. (Pubmed Central) - Mar 15, 2022 The dependencies on absorbed dose for the alveolar, bronchioles, bone surface, heart wall, kidneys, liver, lung, lymphatic nodes, and spleen, are presented. For tumours, the absorbed dose for each drug is calculated separately for a sphere of unit volume by using the information on the injected dose.Conclusion, The ratios of the dose coefficient for the tumour to each organ, indicate that lutetium-177 can be recommended for targeted radionuclide therapy since the dose per tumour is much greater than the dose per organ.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. (Pubmed Central) - Mar 12, 2022 A combination of Caveolin-1 and Sox-2 protein levels was sufficient to maintain high predictive accuracy, which we validated in HNSCC patient tumor samples with known clinical response to cetuximab. These results support further investigation into the combined use of Caveolin-1 and Sox-2 as predictive biomarkers for cetuximab response in the clinic.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Melanoma and eruptive nevi during cetuximab treatment: EGFR inhibitors and a common concern. (Pubmed Central) - Mar 11, 2022 A 59-year-old patient was referred to the Melanoma Unit for a dermatologic consultation due to the eruptive onset of multiple hyperpigmented nevi one-month after the beginning of their medical therapy with cetuximab for metastatic colorectal cancer. No other side-effects were reported, with the exception of a mild cutaneous xerosis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal: Severe anaphylaxis caused by intravenous anti-cancer drugs. (Pubmed Central) - Mar 11, 2022 No other side-effects were reported, with the exception of a mild cutaneous xerosis. We elucidated the high-risk settings of chemotherapy-induced severe anaphylaxis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. (Pubmed Central) - Mar 11, 2022 In this work, all these active targeted nanomedicines are discussed, analyzing their advantages and disadvantages over conventional chemotherapy as well as the challenges involved in their lab to clinical translation. In addition, examples of formulations developed and evaluated at the preclinical level are also discussed.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. (Pubmed Central) - Mar 9, 2022 In NSCLC SCC, a combination index of EGFR FISH plus EGFR IHC results was associated with improved OS when cetuximab was added to CT, representing a potential predictive molecular paradigm for patients suitable for EGFR-antibody therapy. FOLFIRI plus cetuximab is cost-effective compared with FOLFIRI plus bevacizumab or FOLFIRI alone in RAS wild-type left-sided mCRC and patients who undergo resection.
|